Nayid Jana
Program: Neurosciences
Current advisor: Tammie L.S. Benzinger, MD, PhD
Undergraduate university: University of Puerto Rico-Cayey
Research summary
Lecanemab is a new monoclonal antibody treatment for Alzheimer’s disease that was made available on 8/1/23. Many monoclonal antibodies, including lecanemab, can cause ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). The incidence and progression of ARIA depends on the treatment being used. It is often seen early in treatment, usually within the first 7 doses, and many patients are asymptomatic. However, serious life-threatening events such as intracerebral hemorrhages have been observed on patients being treated with this medication. ApoE4 genotype is the major risk factor for developing ARIA. Antithrombotic medications and age have been found to not increase the risk of ARIA.
We aim to see ARIA trends in the radiographic findings of patients on the lecanemab therapy. The key findings that will be reported are any cerebral hemorrhage >10 mm in greatest diameter, microhemorrhages, superficial siderosis, and vasogenic edema. This will provide a comprehensive workflow that radiologists can use to diagnose ARIA, characterize patient symptoms, and guide management.
Graduate publications